论文部分内容阅读
目的:探讨血清抗RA33抗体、RF、CRP联合检测在类风湿性关节炎患者诊断、治疗及预后中的作用。方法:采用ELISA法对35例类风湿性关节炎患者和30例健康对照者进行抗RA33抗体的检测,间接免疫荧光法检测ANA、免疫印迹法检测ENA,免疫比浊法进行类风湿因子(RF)及CRP的检测。结果:类风湿性关节炎患者组RF水平为:[(104.51±153.88)KIU/L]与健康对照组[(10.89±2.78)KIU/L]比较,差异非常显著(p<0.01);类风湿性关节炎组CRP[(11.60±23.24)mg/L]与健康对照组[(2.57±2.18)mg/L]比较,差异显著(p<0.05);类风湿性关节炎组抗RA33抗体水平:[(17.81±35.11)U/mL]与健康对照组[(8.10±8.40)U/mL]比较,差异非常显著(p<0.01)。RF、抗RA33抗体、CRP及ANA诊断类风湿性关节炎的灵敏度分别为:80.00%,34.29%,42.86%,62.86%;RF、抗RA33抗体、CRP及ANA诊断类风湿性关节炎的特异性分别为:93.33%,93.33%,90.00%,96.67%;ENA的检出率均较低。结论:类风湿性关节炎患者抗RA33抗体检出的灵敏度低,但特异性强。对类风湿性关节炎患者进行抗RA33抗体、ANA、RF、CRP、ENA联合检测,对于疾病的进展、病因分析、指导治疗和改善预后均具有重要意义。
Objective: To investigate the role of serum anti-RA33 antibody, RF and CRP in the diagnosis, treatment and prognosis of patients with rheumatoid arthritis. Methods: The anti-RA33 antibody was detected in 35 patients with rheumatoid arthritis and 30 healthy controls by ELISA, ANA was detected by indirect immunofluorescence, ENA was detected by immunoblotting, and rheumatoid factor (RF) ) And CRP testing. Results: The RF level in patients with rheumatoid arthritis was significantly higher than that in healthy controls ([(104.51 ± 153.88) KIU / L] [(10.89 ± 2.78) KIU / L] There was significant difference (P <0.05) between CRP [(11.60 ± 23.24) mg / L] and healthy control group [(2.57 ± 2.18) mg / L] in rheumatoid arthritis group; [(17.81 ± 35.11) U / mL] compared with the healthy control group [(8.10 ± 8.40) U / mL], the difference was significant (p <0.01). The sensitivity of RF, anti-RA33 antibody, CRP and ANA in diagnosis of rheumatoid arthritis were 80.00%, 34.29%, 42.86% and 62.86% respectively. The specificity of RF, anti-RA33 antibody, CRP and ANA in the diagnosis of rheumatoid arthritis Respectively: 93.33%, 93.33%, 90.00%, 96.67%; the detection rate of ENA is low. Conclusion: The anti-RA33 antibody in patients with rheumatoid arthritis has low sensitivity but high specificity. The combination of anti-RA33 antibody, ANA, RF, CRP and ENA in patients with rheumatoid arthritis is of great significance for the progress of the disease, etiological analysis, guiding treatment and prognosis.